New awards seek to highlight how “profit mongering” affects US healthcareBMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k86 (Published 08 January 2018) Cite this as: BMJ 2018;360:k86
- Michael McCarthy
A new annual top 10 list will highlight the year’s “most egregious examples of profit mongering and lack of empathy” in US healthcare, according to the Lown Institute, a health advocacy group based in Boston (http://lowninstitute.org/news/blog/shkreli-awards).
The list has been named the “Shkreli awards” after Martin Shkreli, the “pharma bro” chief executive of Turing Pharmaceuticals, who raised the price of pyrimethamine, a 60 year old generic drug used to treat toxoplasmosis, by 5000%, from $13.50 (£9; €12) to $750 a tablet.1
Vikas Saini, president of the institute, said the goal …